GT Biopharma is trading 6.98% lower at $6.80 pre-market versus the supplied previous close of $7.31; no clear company-specific catalyst was identified. - The investor-relations page lists a September 15 press release as its latest announcement. - The biotech sector was reported higher pre-market and broader market indicators were positive, offering no direct explanation for the decline. - No pre-market volume information was provided.